This article is more than 5 years old. Information may no longer be current.
Nepafenac concentrations similarly effective after PRK
Click Here to Manage Email Alerts
No significant differences in pain scores or presence of haze were seen in patients given two different concentrations of nepafenac ophthalmic suspension at two different frequencies after photorefractive keratectomy, according to a study.
The prospective study of 35 patients who underwent PRK were assigned to receive nepafenac 0.3% ophthalmic suspension once daily in one eye and nepafenac 0.1% ophthalmic suspension three times a day in the contralateral eye from the day of operation until reepithelialization.
Pain was evaluated every 2 hours on the day of the operation and once daily thereafter. The pain scale ranged from 0 to 4, with 0 representing no pain and 4 representing severe constant or sharp pain. Visual acuity and subepithelial haze were also assessed.
Patients were assessed at 2 weeks and at 1, 3, 6 and 12 postoperative months.
At 48 hours, for the study eyes, 66% of patients reported a pain score of zero, compared with 68% of patients reporting a pain score of zero in the control eye. Additionally, no significant differences were found in corneal haze or in uncorrected or corrected distance visual acuity between the two groups at any postoperative timepoint.
At final follow-up, the UDVA was 0.002 logMAR in the nepafenac 0.3% group and 0.008 logMAR in the nepafenac 0.1% group. At 12-months, the CDVA for the nepafenac 0.3% group was 0.013 logMAR, compared with 0.008 logMAR for the nepafenac 0.1% group. – by Robert Linnehan
Disclosures: Kontadakis reports the study was supported by a grant from the Hellenic Society of Intraocular Implant and Refractive Surgery.
Click Here to Manage Email Alerts